RGEN - Repligen Corporation
WALTHAM, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the William Blair 46th Annual Growth Stock Conference in Chicago, IL. Olivier Loeillot, President and Chief Executive Officer, will present a company overview on June 3rd at 10:40 a.m. CT.
WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2025 Corporate Sustainability Report and related reporting framework disclosures. Themed “Driving Sustainable Growth Together”, this report communicates the company's progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities, and Pathways to Success. Also included in the 2025 Sustainability Report are detailed disclosures aligned with the United Nations Sustainable Development Goals (UN SDGs) and three key reporting frameworks: the Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB) Standards and the Task Force on Climate-related Financial Disclosures (TCFD), now part of the IFRS Sustainability Alliance.
Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Bank of America Securities 2026 Global Healthcare Conference, being held May 12-14 in Las Vegas, Nevada.
RGEN tops Q1 earnings and revenue estimates, sending shares higher as strong chromatography and analytics business aid growth. The company raises its 2026 EPS view.
Repligen Corporation (RGEN) Q1 2026 Earnings Call Transcript
Repligen (RGEN) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.39 per share a year ago.
WALTHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2026, covering the three-month period ended March 31, 2026. The Company is also providing updated financial guidance for the full year 2026.
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Class A shares of the Alger Mid Cap Growth Fund underperformed the Russell Midcap Growth Index during the first quarter of 2026. FTAI Aviation Ltd., Vertiv Holdings Co. and Comfort Systems USA, Inc., were among the top contributors to performance. Repligen Corporation, AppLovin Corp., and Carvana Co. were among the top detractors from performance.
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Conestoga SMid Cap Composite returned -10.24% net-of-fees in the first quarter, lagging the Russell 2500 Growth Index's return of -3.52%. RBC's performance was driven by continued strength in aerospace and defense, where demand remains robust and increasingly visible through a growing backlog. Despite a solid quarter, Repligen stock underperformed as investors focused on a more measured outlook and lingering concerns around end-market demand.
Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ET Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ET
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its new Repligen Training & Innovation Center (“RTIC”) at its OPUS® Pre-packed Chromatography Columns manufacturing facility in Breda, the Netherlands. The RTIC buildout, which features product exhibits and purpose-built demonstration areas, was designed to provide customers with pre- and post-sales support, and a hands-on experience with Repligen's innovative bioprocessing solutions.
Massachusetts Financial Services Co. MA acquired a new position in Repligen Corporation (NASDAQ: RGEN) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,215,527 shares of the biotechnology company's stock, valued at approximately $199,176,000. Massachusetts Financial Services Co. MA
Azzad Asset Management Inc. ADV cut its stake in shares of Repligen Corporation (NASDAQ: RGEN) by 59.5% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,314 shares of the biotechnology company's stock after selling 4,869 shares during the quarter. Azzad Asset
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Congress Asset Management Co. grew its position in shares of Repligen Corporation (NASDAQ: RGEN) by 241.4% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 746,306 shares of the biotechnology company's stock after buying an additional 527,714 shares during
Repligen (NASDAQ: RGEN) executives outlined a strategy focused on portfolio breadth, innovation, and commercial execution during a recent discussion with Life Science Analyst Paul Knight. Chief Executive Officer Olivier said he has been with the company about two and a half years and has served as CEO for roughly a year and a half, adding that
Repligen Corporation (RGEN) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript